Author Correction: Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors

Correction to: Acta Pharmacologica Sinica https://doi.org/10.1038/s41401-022-00994-4, published online 17 October 2022

After check of our published article entitled “Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors” in Acta Pharmacologica Sinica, we found that there were misspellings in Fig. 2f, Fig. 6f, Supplementary Fig. S2 and Supplementary Fig. S5. FTIC-A in these figures need to be modified to FITC-A. In addition, Fig. S1a and Fig. S5a should be changed to Fig. S1 and Fig. S5 in the text and the “a” should be deleted in the supplementary figures Fig. S1 and Fig. S5 and corresponding figure legends. The authors apologized for any inconvenience caused to the journal and readers.

Fig. 2

f Apoptosis was detected by flow cytometry in DMS273 and SHP77 cells treated with a range of concentrations of ZIO-101 for 48 h.

Fig. 6

f Apoptosis was detected by flow cytometry in H3F3A knockdown and H3F3A overexpressing DMS273 cells treated as shown in (b). Quantifification of the apoptosis rate was shown in the right panel. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns no signifificance.